FDA moves to fast-track review of three psychedelic drugs for mental health

The FDA said it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts